This website uses cookies to improve your browsing experience. Please read our Privacy Policy for more information on what information we gather and how it is used.
Preferences
Deny AllAccept All

About VITA-FAST

VITA-FAST is the first ever IP Token (IPT) funding longevity science. The IPT supports and governs research into drugs that enhance autophagy, the natural ‘garbage disposal’ built into our bodies cells that gets rid of unwanted protein build up.

According to David Sinclair, Professor of Genetics at Harvard Medical School "when cells spend less energy dividing and more energy in the process of autophagy, which recycles damaged and misfolded proteins. That act of hunkering down ends up being good for prolonged vitality in every organism we’ve studied”

The establishment of the VITA-FAST IPT follows the success of recent pioneering discoveries by Viktor Korolchuk at the University of Newcastle that have shown that autophagy is critical for the maintenance of NAD levels in cells and that NAD deficiency is the key factor leading to death in reduced autophagy cells.

Learn more about the project in our community call with Viktor Korolchuk, or discover key project milestones in the VITA-FAST story below.

The VITA-FAST Story

VitaDAO’s initial support for Artan Bio, via a Sponsored Research Agreement (SRA), has been to fund the design and validation of their engineered suppressor system (VDP-103) in cells with targetable mutations to confirm validity of the approach.

Artan Bio seeks to continue development of the engineered suppressor system beyond the initial project with VitaDAO to further the IP development, and further validate the system in animal models to support preclinical translation and establish a development candidate for use in clinical trials.

December 2021

Funding for Korolchuk Lab project approved by $VITA token holders

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.

See the proposal on Snapshot here

April 2022

Initial screening of >4,000 compounds commenced against novel assays

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.

November 2022

Korolchuk project publishes fundamental results in Developmental Cell

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.

June 2023

$VITA token holders vote to create VITA-FAST - the first longevity IPT by Tokenizing the Korolchuk IP-NFT

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.

October 2023

Compound screening narrowed down to 19 hits

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.

April 2024

Results of compound screening shared with community, 3 Lead Series identified

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.

August 2024

First New Chemical Entities to target autophagy ordered within Lead Series

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit fringilla consectetur. Morbi at arcu odio. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.

VITA-FAST Tokenomics

IP Tokens represent membership in an IP pool containing the IP and R&D data attached to their parent IP-NFT.

Molecules of the Korolchuk IP-NFT are denoted by the token symbol “VITA-FAST.”

The rights of VITA-FAST token holders are governed by the Korolchuk-Free Association of Molecules (FAM) Membership Agreement.

Roadmap

The Viktor Korolchuk lab is currently screening drug-like molecules with a set of novel cellular assays. With these assays the research has identified three lead series of molecules that are currently (H2 24) being taken forward to structural optimization for further development. The next step will test and optimize new chemical entities to find a lead drug candidate and describe the drug's targets.

Once a lead drug and its target are identified, the research will validate the lead molecules in animal models that would serve as the preclinical data to support further development and lead candidate selection. Once positive data has been achieved in the appropriate animal models, we will work with CDMOs on scalability and manufacturing to support IND-enabling studies. From there, clinical studies would commence.

Every step of the project will be governed, reviewed, and approved by $VITA-FAST token holders.

Want to directly influence outcomes in longevity science research?

Get $VITA-FAST